Overview
I am a quantitative epidemiologist with methodological expertise in the design and analysis of observational studies that leverage data from cohort studies, registries, and the electronic health record (EHR). My background, training, and research is in the measurement and characterization of biomarkers, risk factors and treatment outcomes for chronic disease using real-world datasets. My primary research interests are in the use of novel sources of data, including the EHR, to conduct chronic disease research at the intersection of informatics, biostatistics, and epidemiology. My ongoing work aims to integrate informatics, epidemiology, and biostatistics to reduce the burden of chronic disease. I have topical expertise in multiple chronic diseases, including oncology, cardiovascular disease, and chronic kidney disease. In parallel, I have a portfolio of research that aims to understand the impact of social determinants of health, including dynamic neighborhood changes, such as gentrification, on the health of adults and children.
Current Appointments & Affiliations
Recent Publications
Low uptake and disparities in therapeutic inertia of cardiorenal protective diabetes medications for patients with type 2 diabetes and above-target hemoglobin A1c.
Journal Article BMJ Open Diabetes Res Care · April 22, 2026 INTRODUCTION: Therapeutic inertia (failure to initiate or intensify therapy when therapeutic goals are unmet) contributes to poor glycemic control and diabetes-related complications. We assessed the extent of therapeutic inertia, defined as a lack of new p ... Full text Link to item CiteReal-world early quality of life (QOL) changes on IO-based regimens in the prospective observational ODYSSEY metastatic renal cell carcinoma (mRCC) study.
Conference Journal of Clinical Oncology · March 1, 2026 Lack of standardized reporting and collection of patient-reported outcomes (PROs) limits cross-trial comparisons of first-line IO-based regimens for mRCC. Prospectively collected real world data may fill this important knowledge gap. Pts with stable/improv ... Full text CiteOff-label use of alemtuzumab, belatacept, and rapamycin in kidney transplantation-Long-term real-world experience.
Journal Article Am J Transplant · January 2026 Conventional immunosuppressive regimens in kidney transplantation continue to pose significant challenges, largely due to their reliance on calcineurin inhibitors (CNIs) and corticosteroids. These challenges have driven the search for alternative regimens ... Full text Link to item CiteRecent Grants
1/3 CTSA UM1 at Duke University
ResearchFaculty Member · Awarded by National Institutes of Health · 2025 - 2032Sc2i Competitive Renewal
ResearchCo Investigator · Awarded by Henry M. Jackson Foundation · 2021 - 2027Surgical Critical Care Initiative (SC2i): Civilian application of military decision support tools for critically injured patients
ResearchPrincipal Investigator · Awarded by Henry M. Jackson Foundation · 2023 - 2027View All Grants